2. Search Result
Search Result
Results for "

opioid-induced constipation

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0118A
    Naloxegol oxalate
    2 Publications Verification

    NKTR-118 oxalate; AZ-13337019 oxalate

    		 Opioid Receptor Neurological Disease
    Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .
    Naloxegol oxalate
  • HY-19627A
    Naldemedine tosylate

    S-297995 tosylate

    		 Opioid Receptor Neurological Disease Metabolic Disease
    Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine tosylate is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
    Naldemedine tosylate
  • HY-A0118
    Naloxegol

    NKTR-118; AZ-13337019

    		 Opioid Receptor Neurological Disease
    Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .
    Naloxegol
  • HY-144606
    Mu opioid receptor antagonist 1

    		Opioid Receptor Neurological Disease
    Mu opioid receptor antagonist 1 (compound 19) is a selective and orally active μ opioid receptor (MOR) ligand with an Ki value of 0.58 nM and an EC50 of 1.15 nM. Orally administrating with Mu opioid receptor antagonist 1 increases intestinal motility during morphine-induced constipation. Mu opioid receptor antagonist 1 can be used for researching opioid-induced constipation (OIC) .
    Mu opioid receptor antagonist 1
  • HY-19627
    Naldemedine

    S-297995

    		 Opioid Receptor Neurological Disease Metabolic Disease
    Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
    Naldemedine
  • HY-B0680
    Lubiprostone (hemiketal)

    RU-0211 (hemiketal); SPI-0211 (hemiketal)

    		 Chloride Channel Others Cancer
    Lubiprostone (hemiketal) (RU-0211 (hemiketal)) is a selective chloride channel 2 (CLCN2) activator. Lubiprostone (hemiketal) is used to treat chronic idiopathic constipation and opioid-induced constipation by activating CLCN2 channels to increase chloride ion secretion in the intestine, thereby increasing intestinal fluid secretion and enhancing intestinal peristalsis. Lubiprostone (hemiketal) can be used in the study of chronic constipation and cancer .
    Lubiprostone (hemiketal)
  • HY-A0118AS
    Naloxegol-d5 oxalate

    		Isotope-Labeled Compounds Opioid Receptor Neurological Disease
    Naloxegol-d5 (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation[1][2].
    Naloxegol-d5 oxalate
  • HY-16765
    Axelopran

    TD-1211

    		 Opioid Receptor Others
    Axelopran (TD-1211) is an antagonist for opioid receptor, with pKi of 9.8, 8.8 and 9.9, for human recombinant μ and δ receptors and guinea pig κ receptors, respectively .
    Axelopran

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: